Alpha 2.0
Login Register
» Authors » Nicholas Lintzeris

Nicholas Lintzeris

Explore the profile of Nicholas Lintzeris including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 189
Citations 2401
Followers 0
Related Specialties
Psychiatry
General Medicine
Pharmacology
Top 10 Co-Authors
Raimondo Bruno
Louisa Degenhardt
Suzanne Nielsen
Briony Larance
Adrian Dunlop
Michael Farrell
Llewellyn Mills
Gabrielle Campbell
Iain S McGregor
Robert Ali
Published In
Drug Alcohol Rev
Drug Alcohol Depend
Med J Aust
Addiction
Pain Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Bridging the evidence and the politics: Implementation trial of supervised injectable opioid treatment (SIOT) in Australia
Ritter A, Bell J, Strang J, Ezard N, Rodgers C, Belackova V, et al.
Int J Drug Policy . 2025 Mar; 138:104749. PMID: 40037105
Supervised Injectable Opioid Treatment (SIOT) targets people experiencing opioid dependence who have not benefited from existing treatments. In this population, SIOT has been demonstrated to be efficacious and effective, yet...
2.
Evaluation of an online postal take-home naloxone service
Harrod M, Sunjic S, Pepolim L, Aylmer R, Skelley N, Lintzeris N
Drug Alcohol Rev . 2025 Feb; 44(3):696-703. PMID: 39988370
Introduction: New South Wales User AIDS Association established a pilot postal take-home naloxone (THN) service to enhance access to THN for people unable or unwilling to attend existing services providing...
3.
Design considerations for medicinal cannabis clinical trials in people receiving palliative care
Razmovski-Naumovski V, Martin J, Chye R, Phillips J, Lintzeris N, Solowij N, et al.
J Pain Symptom Manage . 2025 Feb; PMID: 39988015
Context: Evaluating medicinal cannabis in clinical trials is important for informing its efficacy and safety in clinical care. Alongside the inherent practical challenges of conducting clinical trials in people receiving...
4.
Trial protocol of an open-label pilot study of oral ltrexone-propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
Siefried K, Acheson L, Clifford B, Moller C, Brett J, Christmass M, et al.
BMJ Open . 2025 Feb; 15(2):e092032. PMID: 39920060
Introduction: Methamphetamine use disorder is a global public health concern with no approved pharmacotherapies for its treatment. One recent randomised controlled trial conducted in the USA examined a combination of...
5.
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings
White B, Little S, Haber P, Roberts J, Nolan E, Lintzeris N, et al.
Drug Alcohol Rev . 2025 Feb; 44(2):640-648. PMID: 39901317
Introduction: A trial of long-acting injectable buprenorphine (LAIB) in Australian prisons allowed examination of treatment satisfaction and patient-reported outcomes. Methods: UNLOC-T was a 16-week non-randomised open-label study. Men and women...
6.
Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial
Ezard N, Clifford B, Siefried K, Ali R, Dunlop A, McKetin R, et al.
Addiction . 2024 Dec; PMID: 39701142
Aims: This study tested the efficacy and safety of a 12-week course of lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements in health and wellbeing, in...
7.
Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-label, Nonrandomized Clinical Trial
Tremonti C, Blogg J, Jamshidi N, Harjanto R, Miles N, Ismay C, et al.
J Addict Med . 2024 Dec; 19(1):75-82. PMID: 39625175
Aims: To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers. Methods: We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing...
8.
Integration of a facilitated access pathway for contraception into alcohol and other drug treatment services: A cohort study comparing metropolitan and regional settings
McNamara K, Murnion B, Lintzeris N, Chase V, Black E, Malcolm A, et al.
Drug Alcohol Rev . 2024 Oct; 44(1):166-178. PMID: 39380287
Introduction: Women who attend alcohol and other drug (AOD) services experience higher rates of unintended pregnancy, and access less contraception, than the general population. This study aims to observe contraceptive...
9.
Provider costs of treating opioid dependence with extended-release buprenorphine in Australia
Settumba S, Shahbazi J, Byrne M, Degenhardt L, Grebely J, Larance B, et al.
Drug Alcohol Rev . 2024 Oct; 44(1):179-194. PMID: 39370671
Introduction: The costs of providing medication-assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended-release buprenorphine (BUP-XR), we performed a bottom-up...
10.
Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost
Rodgers C, Siefried K, Ritter A, Belackova V, Treloar C, Jauncey M, et al.
BMJ Open . 2024 Aug; 14(8):e082553. PMID: 39097309
Introduction: Supervised injectable opioid treatment (SIOT) is an evidence-based intervention targeting opioid-dependent people for whom existing treatments have been ineffective. This project will primarily assess the feasibility and the acceptability...